Background The quality of reporting of harms data in randomised controlled trials (RCTs) has been reported to be suboptimal. Rheumatoid arthritis (RA) has seen a massive growth in novel pharmacotherapies in the last decade. Objective The aim of this study was to assess the quality of reporting of harms-related data in RCTs evaluating pharmacological interventions for RA according to the CONSORT (Consolidated Standards of Reporting Trials) statement on harms reporting extension. Study selection RCTs published between January 2011 and August 2016 in the five highest impact factor journals in general medicine and two in rheumatology subject categories as per 2015 Journal Citation Reports were included. Reports of secondary, supplementary or exploratory analyses of RCTs and non-inferiority trials were excluded. Two reviewers independently extracted data using a structured, pilot-tested, 18-item questionnaire developed based on CONSORT harms extension recommendations. Findings 68 RCTs were included in the review. Out of a maximum harms reporting score of 18, the mean (SD) score was 8.51 (3.5) (range=0-15). More than half (56.5%) of the RCTs reported ≤50% of items and only three (4.3%) RCTs reported more than 70% (score ≥14) of the items. Multilinear regression analyses found that region of trial origin (p=0.01), sample size (p=0.001) and whether the study was a long-term extension of a trial or not (p=0.04) were independent predictors associated with higher total harms reporting score. Conclusions The adherence to CONSORT harms extension was poor in recently published RCTs of pharmacological interventions for RA. There is a need to improve quality of harms reporting in RCTs to allow transparent and balanced assessment of the benefit-risk ratio in clinical decision making.
Introduction
Adequate and transparent reporting of both effectiveness and harms data in randomised controlled trials (RCTs) is critical to allow clinicians to make an informed and balanced decision about the benefit-risk ratio of a particular drug/treatment. Suboptimal reporting of adverse events (AEs) may create false perceptions of drug safety among clinicians leading to medication errors. 1 Transparent, comprehensive and accurate reporting of AEs is important to ensure that clinicians make the appropriate decision for their patients, and for the patients (the consumers of medicines) to understand the risk associated with treatment, and for the regulatory agencies in approving and/or withdrawing a drug from the market. In 2004, the harms extension of Consolidated Standards of Reporting Trials (CONSORT) was first published with an aim to improve quality of reporting of AEs in RCTs. 2 The original CONSORT statement 3 did not provide any specific guidance on reporting of harms-related data; however, the 2001 revision 4 included a single item, still inadequate given the critical importance of harms data in clinical decision making. This prompted the development of the 2004 CONSORT harms extension. The CONSORT statement has improved quality of reporting of RCTs. [5] [6] [7] [8] However, the reporting of AEs in
RCTs still remains suboptimal. 1 9-14 A number of studies have found deficiencies and inaccuracies in relation with reporting of harms data in RCTs. Alarmingly, even important AEs are often under-reported. 1 9-14 Rheumatoid arthritis (RA) is a common inflammatory arthritis where pharmacological therapy with disease-modifying antirheumatic drugs (DMARDs) is paramount and where a large number of new agents have been introduced in the last decade. Many of these are biological agents with potential for serious adverse effects. The aim of this systematic review was to evaluate the quality of reporting harms-related data in RCTs evaluating the effectiveness of pharmacological interventions for RA published in the top-tier medical journals.
Methods

Study selection
We selected the top five highest impact factor journals in general and internal medicine subject category which included the New England Journal of Medicine (NEJM), the Lancet, the Journal of American Medical Association (JAMA), the British Medical Journal (BMJ), and the Annals of Internal Medicine, and the top two journals in rheumatology subject category which included the Annals of Rheumatic Diseases and the Arthritis & Rheumatology as per the 2015 Journal Citation Reports (JCR). Although Nature Reviews Rheumatology has the second highest impact factor in the rheumatology subject category in 2015 JCR, it was not included in this review as the journal does not publish primary research. Subsequently, Arthritis & Rheumatology, ranked as number 3 in the rheumatology category, was included. These journals were selected based on the assumption that the quality of reporting of RCTs in these top-tier journals is likely to be the best due to their rigorous peer-review and high-standard editorial checks during the submission and publication processes. The implications of using only a certain number of journals are discussed in the Limitations section.
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We searched Medline (via OVID) for RCTs evaluating the effectiveness of pharmacological interventions for the treatment of RA. To identify the recent RCTs, we selected studies published between January 2011 and August 2016 in order to look at the latest trends in AEs reporting. The search was performed in August 2016 and a highly sensitive filter for detecting RCTs, developed by an expert health sciences librarian, was used together with the keyword 'rheumatoid arthritis' (See online supplementary appendix 2). The following studies were excluded: phase I or II RCTs; secondary, exploratory or pooled analysis of RCTs; non-RA RCTs; non-inferiority RCTs; RCTs of non-pharmacological interventions and systematic reviews and meta-analysis. Reports of long-term extensions (LTEs) of RCTs were included in the review.
All search results were transferred to an Endnote file. After deduplication, the titles and abstracts were screened by one reviewer and full texts of the relevant articles were retrieved. The RCTs meeting the inclusion/exclusion criteria were included in the review. was calculated by summing up all the individual scores with maximum and minimum scores of 18 and 0, respectively. In addition, data about trial characteristics (eg, year of publication, journal, funding agency, trial origin) were also extracted using a structured form. Both the trial characteristics questionnaire and the 18-item checklist were piloted on six of the included RCTs. For all included studies, data were extracted by two reviewers independently. Discrepancies were resolved through discussion until a census was reached. In addition to full text, where available, supplementary files and data associated with included trials were also used to extract any relevant data. For this review, the terms 'harms' and 'adverse events (AEs)' have been used interchangeably, as appropriate. A multivariate linear regression model was developed using a stepwise forward approach to identify predictors associated with higher THRS. Statistical assumptions for multilinear regression modelling including homoscedasticity, multicollinearity and multivariate normality were also tested and satisfied. All statistical tests were two sided and a p value less than 0.05 was considered statistically significant.
Data extraction and development of harms reporting scoring system
Results
Characteristics of RCTs included
Of the 347 records identified from the database search, the titles and abstract of 283 studies were screened after deduplication. Full texts of 146 studies were assessed for eligibility and 68 studies were included in the review (online supplementary appendix 1). The PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) flow Evidence synthesis: General medicine diagram including the reasons for exclusions is provided in figure 1 . No RCTs were identified from JAMA and BMJ but more than two-thirds of the included trials (53; 77.9%) were published in Annals of Rheumatic Diseases and were funded by pharmaceutical industry (53; 77.9%) (table 1) . Almost all RCTs were multicentre (66; 97.1%) and more than half had intercontinental origin (37; 54.4%). Most of the RCTs (57; 82.6%) evaluated the effectiveness of a biological agent alone or in combination with other drugs used in the treatment of RA. Results of the primary efficacy outcome were reported to be positive (investigational arm more effective than the control arm) by most of the RCTs included in the review (56; 82.3%). The toxicity profile of the investigational arm was concluded by the authors to be equivalent/comparable to the control arm in more than half of the RCTs (40; 58.0%). In 27 (39.7%) trials, the funding agency had a role in designing or reporting of the trial. Further details of the characteristics of the RCTs are presented in table 1.
Reporting of the expanded CONSORT harms items
For the total 18 items, more than half of the RCTs reported less than 50% (n=9) of the CONSORT items and only 3 (4.3%) RCTs reported more than 70% of the items. The number (and percentages) of the RCTs fulfilling each of CONSORT harms recommendations are presented in table 2. More than two-thirds of the RCTs (53; 76.8%) mentioned AEs in the title or abstract (CONSORT recommendation 1). However, only a few trials provided information on AEs in the introduction section (9; 13.0%), used a validated scale to measure severity of AEs (8; 11.6%) and gave a definition of AEs (9; 13.0%) (CONSORT recommendations 2 and 3). Less than one-third of the trials (20; 29.0%) described how AE-related data were collected (CONSORT recommendation 4 (4a)). Less than a quarter of the trials (16; 23.2%) described methods of presenting and/or analysing AEs (CONSORT recommendation 5). A vast majority of RCTs described AEs leading to death (60; 87.0%) and number of withdraws caused by AEs in each arm (59; 85.5%). 
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However, slightly more than a quarter (18; 26.1%) of RCTs provided a description of the AEs which resulted in patient withdrawals (CONSORT recommendation 6). The majority of trials presented results for each arm separately (63; 91.3%) and presented a balanced discussion on both safety and efficacy of drug (46; 66.7%) (CONSORT recommendations 8 and 10).
Harms reporting score and associated trials characteristics Out of a maximum score of 18, the mean THRS was 8.51 (SD 3.5) (range 0-15). The mean THRS was significantly higher for those RCTs published in general medicine journals as compared with rheumatology journals (p=0.02) (table 3) . Similarly, the quality of harms reporting score was significantly higher for RCTs involving biologicals (p=0.07), of intercontinental origin (p=0.001) and with a sample size more than 500 participants (p=0.001) compared with RCTs of non-biologicals, regional/national trials and trials involving ≤200 participants, respectively. Interestingly, the RCTs where the trial sponsor had no role for any aspect of designing and/or reporting of the trial had lower total scores as compared with the RCTs in which the trial sponsor played a role in at least one aspect of trial design or reporting (p=0.004) (table 3) . Multiple linear regression analysis was undertaken to identify predictors of higher THRS (table 4). Region of trial origin (intercontinental vs others) (p=0.01), sample size (≤200 vs >200) (p=0.001) and whether the study was a LTE of a trial or not (p=0.04) were found to be independent predictors associated with higher THRS. Intercontinental RCTs had a THRS on an average of 1.9 points higher than national/regional RCTs (95% CI 0.3 to RCT, randomised controlled trial.
Evidence synthesis: General medicine 3.5) . Similarly, trials with a sample size >200 had THRS on an average of 2.9 points higher than RCTs with ≤200 patients (95% CI 1.2 to 4.6). Journal type, funding source and type of drug were not significantly associated with higher THRS. The model explained 36% variation in THRS (table 4) . 
Methods of presenting harms data
Discussion
This review assessed the quality of reporting of harms-related data in RCTs evaluating pharmacological interventions for the treatment of RA in seven top-tier general medicine (five) and rheumatology (two) journals. In general, the adherence to CONSORT harms extension was poor in recently published RCTs. Previously, a review has evaluated the quality of harms reporting in RCTs of non-pharmacological interventions for rheumatic diseases published between 1999 and 2005 and found it to be suboptimal. 16 We found great variations in the reporting of individual items of CONSORT harms extension across trials. Some of the recommendations including: mentioning AEs in the title or abstract (CONSORT item 1); providing number of withdrawals in each arm (item 6a); describing of AEs leading to death (item 6b); separate reporting of results for each arm (item 8a); and separate reporting of severe/serious AEs (item 8b) were adequately reported by the majority of RCTs.
However, certain critical elements including: description of AEs leading to withdrawals (item 6b); process of attributing AEs to trial drug (item 4 c); description of methods for presenting and analysing AEs (item 5); and using a validated instrument to report AE severity were poorly reported. It is possible that authors might have collected this information but could not report it due to restrictions on manuscript length. Manuscript length can be one of the reasons for not adequately reporting AEs. 9 The option of 'online only' supplement is offered by almost all journals now which could be used to report additional harms-related data. The mean THRS for RCTs that were industry funded was significantly higher than for non-industry-funded RCTs. However, industry funding was not found to be an independent predictor in multiple linear regression. Country of trial origin, sample size and whether the study was a LTE of a previously published trial or not were independent predictors significantly associated with higher THRS. Reviews evaluating quality of harms reporting in oncology 9 and analgesic 10 RCTs also reported better reporting of AEs in trials funded by industry. This may be explained by tighter control by regulatory agencies for industry-funded trials, better and thorough data collection capabilities and soliciting services of professional medical writers in manuscript writing. 9 Lower THRS for LTEs found in the present study can be attributed to authors' assumption that AEs have already been sufficiently reported in the primary paper Evidence synthesis: General medicine and need not be reported again in LTEs. However, this is a false assumption as thorough and transparent collection and reporting of all AEs is critically important for LTEs as well as to establish the long-term safety of drugs and to identify rare AEs. 1 We found that AEs reporting was significantly better for RCTs evaluating biologicals compared with non-biologicals. This is perhaps the use of biologicals for the treatment of RA is relatively new and there are reservations regarding their safety, especially long-term safety. On the other hand, safety profiles are well established for traditional DMARDs and this may have prompted authors to focus primarily on the efficacy rather than safety.
In line with our study findings, a number of reviews assessing the quality of AE reporting in various medical specialties have reported critical inadequacies in reporting of AEs. 1 9-12 15 Underdetection and inaccurate reporting of AEs in RCTs and in clinical practice can have serious negative consequences in relation to ensuring patient safety. 1 Empirical research exploring the reasons of under-reporting of harms-related data in RCTs is almost non-existent. Various reasons including manuscript length, neglecting accurate collection, interpretation and presentation of harms data, and lack of authors' interest in reporting harms data have been cited in the literature for under-reporting of harms data. 1 9 10 17 Another challenge commonly encountered by clinicians is to establish a cause-effect relationship between a particular side effect and investigational drug especially when the patient is taking multiple drugs with overlapping toxicity profiles and when disease symptoms/ complications are similar to adverse effects. There is a need to do more advocacy by creating awareness of the CONSORT harms extension recommendations through endorsement, undertaking more research about quality of harms reporting and implementing stringent editorial processes to ensure adherence to CONSORT harms recommendations. Only one of the seven included journals, the Lancet, explicitly recommends authors to follow the CONSORT harms extension in their instructions to authors. However, all these journals require all submitted RCT reports to follow the 2010 CONSORT statement. 18 Furthermore, since 2004 the CONSORT harms extension has received only 604 citations in SCOPUS to date (date of search 9 November 2016) compared with over 3000 citations for the 2010 CONSORT statement which was published in multiple medical journals. This clearly shows that adequate and accurate reporting of harms data, despite its critical importance, is less emphasised and left to the discretion of authors. We suggest that journals should make it compulsory for authors of RCTs to submit a CONSORT harms extension checklist at manuscript submission, with the page number identified where an item has been reported. Although burdensome, peer reviewers could countercheck the methods for collecting, presenting and analysing harms data against the protocol and trial registry. These measures are likely to improve reporting of AEs in RCTs allowing clinicians and patients to understand risks associated with a particular treatment.
Limitations
There are several methodological limitations which should be considered when interpreting the review findings. First, the findings of the review may not be generalisable to non-RA RCTs published in the same journals and/or RCTs published in other journals. There is also potential for publication bias in relation to selection of journals as only seven journals were searched. However, it should be noted here that the selected journals are among the most cited and respected journals in their respective subject categories. Therefore, the quality of reporting of AEs in these journals is likely to be at least comparable to other journals, if not superior. Second, more than two-thirds of the RCTs included in the review were published in Annals of Rheumatic Diseases which might have significantly influenced the overall findings of the review as journals usually have a 'pre-specified' style of reporting RCTs. However, given that none of the RCTs reported all the CONSORT harms extension items and only three RCTs reported more than 70% (13 out of 18) of the items clearly indicates that journal's 'pre-specified' style is unlikely to play a major role in suboptimal reporting of harms-related data in RCTs. Furthermore, under-reporting of harms-related data documented previously in other medical specialties further supports the argument that there are other reasons beyond the journals' style contributing to under-reporting. Third, we only reviewed published trial report and supplementary files but did not review trial protocol and trial registry. It is possible that authors might have defined and described certain elements of CONCORT harms recommendations (eg, definition of AEs, methods of presenting and analysing harms data) in the protocol but not in the final paper. However, the CONSORT statement recommends that this information should be included in the final report as well. Finally, each item in the checklist was weighted and scored equally irrespective of its importance in clinical decision making. For example, AEs information mentioned in the introduction (item 1) is far less important than the description of AEs leading to death (item 6) in order to assess benefit-risk ratio. Although previously used frequently in the literature, reporting a cumulative score (THRS) (by adding each item score) is not recommended by the CONSORT harms extension. However, weighing each item equally was in line with CONSORT recommendations 2 as it does not give priority to any item over the other because these recommendations provide generic guidance on harms reporting not a scoring system to assess quality of harms reporting. Therefore, THRS may not truly reflect deficiencies in reporting of individual items of CONSORT recommendations. Until the CONSORT harms extension is revised and updated, the currently available version should be implemented as 'minimum acceptable standard' for reporting harms data irrespective of the impact of individual items on the assessment of benefit-risk ratio in clinical decision making. In the present study, in order to ensure transparency of study findings, data on both individual items and overall score have been presented (table 2) .
Conclusion
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